Department of Neurology, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Los Angeles, CA 90095-1769, USA.
Biomark Med. 2011 Oct;5(5):537-44. doi: 10.2217/bmm.11.62.
Epilepsy is the most common serious primary disease of the brain, accounting for 1% of the global burden of disease. Diagnosis and treatment suffer from a lack of reliable biomarkers for either epileptogenicity, the presence and severity of an epilepsy condition, or epileptogenesis, the development and progression of an epilepsy condition. The identification of reliable biomarkers would greatly facilitate differential diagnosis, eliminate the current trial-and-error approach to pharmacotherapy, facilitate presurgical evaluation, and greatly improve the cost-effectiveness of drug discovery and clinical trials of agents designed to treat, prevent and cure epilepsy. Identification of reliable biomarkers of epileptogenicity and epileptogenesis for research and clinical applications is a high-priority goal for the epilepsy community. Recent advances in electrophysiology, neuroimaging, molecular biology and genetics promise to reveal clinically useful biomarkers for epilepsy in the near future.
癫痫是最常见的严重原发性脑部疾病，占全球疾病负担的 1%。无论是致痫性、癫痫的存在和严重程度，还是癫痫发生、癫痫的发展和进展，其诊断和治疗都缺乏可靠的生物标志物。可靠的生物标志物的识别将极大地促进鉴别诊断，消除当前药物治疗的试错方法，促进术前评估，并极大地提高药物发现和旨在治疗、预防和治愈癫痫的药物临床试验的成本效益。识别致痫性和癫痫发生的可靠生物标志物，用于研究和临床应用，是癫痫界的一个高度优先目标。电生理学、神经影像学、分子生物学和遗传学的最新进展有望在不久的将来揭示出对癫痫具有临床应用价值的生物标志物。
